Effect of decreasing afferent vagal activity with ondansetron on symptoms of bulimia nervosa: A randomised, double-blind trial

Lancet

Volumn 355, Issue 9206, 2000, Pages 792-797

  Faris, Patricia L ^a,c   Kim, Suck Won ^a   Meller, William H ^a   Goodale, Robert L ^b   Oakman, Scott A ^a   Hofbauer, Randall D ^a   Marshall, Anne M ^a   Daughters, Randall S ^a   Banerjee Stevens, Devjani ^a   Eckert, Elke D ^a   Hartman, Boyd K ^a  

^a Division of Neuroscience Research   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ONDANSETRON; SEROTONIN 3 RECEPTOR; SEROTONIN ANTAGONIST;

ADULT; ARTICLE; BULIMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FEEDING BEHAVIOR; FEMALE; HUMAN; NEUROTRANSMISSION; PRIORITY JOURNAL; SATIETY; SYMPTOM; TIME; TREATMENT OUTCOME; VAGUS NERVE; VOMITING;

EID: 0034603587     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(99)09062-5     Document Type: Article

References (28)

1. Hsu LK. Epidemiology of the eating disorders. Psychiatr Clin North Am 1996; 19: 681-700.
2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. Washington, DC: American Psychiatric Association, 1994.
3. Keel PK, Mitchell JE. Outcome in bulimia nervosa. Am J Psychiatry 1997; 154: 313-21.
4. Faris PL, Raymond NC, de Zwaan M, et al. Nociceptive, but not tactile, thresholds are elevated in bulimia nervosa. Biol Psychiatry 1992; 32: 462-66.
5. Hadigan CM, Walsh BT, Devlin MJ, et al. Behavioral assessment of satiety in bulimia nervosa. Appetite 1992; 18: 233-41.
6. Halmi KA, Sunday SR. Temporal patterns of hunger and fullness ratings and related cognitions in anorexia and bulimia. Appetite 1991; 16: 219-37.
7. Blundell J. Pharmacological approaches to appetite suppression. Trends Pharmacol Sci 1991; 12: 147-57.
8. Lautenbacher S, Pauls AM, Strian F, et al. Pain sensitivity in anorexia nervosa and bulimia nervosa. Biol Psychiatry 1991; 29: 1073-78.
9. de Zwaan M, Biener D, Bach M, et al. Pain sensitivity, alexithymia, and depression in patients with eating disorders: are they related? J Psychosom Res 1996; 41: 65-70.
10. Randich A, Gebhart GF. Vagal afferent modulation of nociception. Brain Res Rev 1992; 17: 77-99.
11. Hartman BK, Faris PL, Kim SW, et al. Ondansetron in bulimia nervosa (letter). Arch Gen Psychiatry 1997; 54: 969-70.
12. Freeman AJ, Cunningham KT, Tyers MB. Selectivity of 5-HT3 receptor antagonists and anti-emetic mechanisms of action. Anticancer Drugs 1992; 3: 79-85.
13. Galligan JJ. Electrophysiological studies of 5-hydroxytryptamine receptors on enteric neurons. Behav Brain Res 1996; 73: 199-201.
14. Champaneria S, Costall B, Naylor RJ, et al. Identification and distribution of 5-HT3 recognition sites in the rat gastrointestinal tract. Br J Pharmacol 1992; 106: 693-96.
15. Blackshaw LA, Grundy D. Effects of 5-hydroxytryptamine on discharge of vagal mucosal afferent fibres from the upper gastrointestinal tract of the ferret. J Auton Nerv Syst 1993; 45: 41-50.
16. Reynolds DJ, Barber NA, Grahame SD, et al. Cisplatin-evoked induction of c-fos protein in the brainstem of the ferret: the effect of cervical vagotomy and the anti-emetic 5-HT3 receptor antagonist granisetron (BRL 43694). Brain Res 1991; 565: 231-36.
17. Fukui H, Yamamoto M, Sato S. Vagal afferent fibers and peripheral 5-HT3 receptors mediate cisplatin-induced emesis in dogs. Jpn J Pharmacol 1992; 59: 221-26.
18. Ohuoha DC, Knable MB, Wolf SS, et al. The subnuclear distribution of 5-HT3 receptors in the human nucleus of the solitary tract and other structures of the caudal medulla. Brain Res 1994; 637: 222-26.
19. Morales M, Battenberg E, de Lecea L, et al. Cellular and subcellular immunolocalization of the type 3 serotonin receptor in the rat central nervous system. Mol Brain Res 1996; 36: 251-60.
20. Simpson KH, Murphy P, Colthup PV, et al. Concentration of ondansetron in cerebrospinal fluid following oral dosing in volunteers. Psychopharmacology (Berl) 1992; 109: 497-98.
21. First M, Spitzer R, Gibbon M, et al. Structured clinical interview for DSMIV (SCID). New York: New York State Psychiatric Institute, 1994.
22. Cooper Z, Fairburn C. The eating disorder examination: a semi-structured interview for the assessment of specific psychopathology of eating disorders. Int J Eat Disord 1987; 6: 1-8.
23. Hamilton M. A rating scale for depression. J Neurol, Neurosurg, Psychiatry 1960; 23: 56-62.
24. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961; 4: 53-63.
25. Hamilton M. A rating scale for anxiety. Br J Med Psychol 1959; 32: 50-55.
26. Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol 1988; 56: 893-97.
27. Fawcett J, Epstein P, Fiester SJ, et al. Clinical management -imipramine/placebo administration manual. NIMH Treatment for Depression Collaborative Research Program. Psychopharmacol Bull 1987; 23: 309-24.
28. Faris PL, Kim SW, Meller WH, et al. Effect of ondansetron, a 5-HT3 receptor antagonist, on the dynamic association between bulimic behaviors and pain thresholds. Pain 1998; 77: 297-303.